How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

£4.3bn

adjusted R&D investment in 2019

39

new medicines in development at FY 2019

15

new vaccines in development at FY 2019

 

 

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

£33.8bn

total turnover in 2019

£9bn

adjusted operating profit in 2019

£5.1bn

free cash flow in 2019

£4bn

dividends paid in 2019

 

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 

78%

employee engagement score on our latest employee survey

£263m

donated in 2019 to community health programmes

1st

in Access to Medicines Index since the assessment began in 2008